Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
The global community-acquired bacterial pneumonia (CABP) treatment drugs market is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).

The increasing prevalence of community-acquired pneumonia is expected to propel growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market

Get PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/4269

High prevalence of community-acquired pneumonia is expected to propel demand for community-acquired bacterial pneumonia (CABP) treatment drugs, which is expected to drive the market growth over the forecast period. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that the incidence of all?cause CAP each year was estimated at 0.81 per 1,000 individuals , rising to 6.95 per 1,000 person year in those aged 75 or older in Central Vietnam.

Moreover, increasing incidence of CAP were dominated by the effect of HIV. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in 2017, the incidence of CAP were dominated by HIV if untreated, which was associated with a 17? to 35?fold increase in pneumococcal pneumonia in Sub-Saharan Africa region.

However, inappropriate treatment due to incorrect identification of pathogen contribute to the limited use of current drugs in the management of CABP. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), the presence of multiple pathogens in patients leads to incorrect selection of initial antibiotic, which may affect the mortality outcome in CABP. Such inappropriate medication are expected to hamper the market growth.

Increasing incidence of CAP in North America is expected to boost the market growth

North America is expected to hold dominant position in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, owing to rising incidence of community-acquired pneumonia in the region especially in the U.S. For instance, according to the Asian Pacific Society of Respirology, an article published in 2017, reports that in the U.S. overall incidence of community-acquired pneumonia in adults was around 2.5 per 1000 person, rising to 6.3 and 16.4 per 1000 person in adults aged 65-79 and 80 years or older in 2017. Furthermore, according to the Centers for Disease Control and Prevention (CDC), an article published in 2018 states that, around 6 million cases of community-acquired pneumonia were reported annually, resulting in an estimated 4.2 million ambulatory care visits, with adults age 65 and older most vulnerable to CAP.

Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global community-acquired bacterial pneumonia (CABP) treatment drugs market during the forecast period.

Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/4269

Key Players
Major players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.

About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]